Veris Health and Ohio State University Cancer Center Launch Commercial Digital Cancer Care Platform
核心洞察
Veris Health (搜索) and The Ohio State University Comprehensive Cancer Center have launched the commercial phase of their strategic partnership to deploy the Veris Cancer Care Platform across the cancer center.
The digital platform provides remote physiological monitoring, symptom reporting, and telehealth capabilities to enhance personalized cancer care and reduce unplanned hospitalizations.
Cancer patients receive a VerisBox of connected healthcare devices that transmit physiologic data to clinicians via cellular connections, with a complementary smartphone app for symptom reporting.
PAVmed's majority-owned digital health subsidiary Veris Health (搜索) and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have launched the commercial phase of their long-term strategic partnership agreement to deploy the Veris Cancer Care Platform across the NCI-designated comprehensive cancer center.
"We are pleased to move into the commercial phase of our partnership with The James at OSU, one of the largest and most prestigious academic cancer centers in the nation, to expand clinical deployment of our platform to enhance personalized cancer care," said Brian deGuzman, M.D., Chief Operating Officer of Veris Health (搜索). "This represents an important milestone on the path towards reaching Veris' long-term commercial potential."
Platform Capabilities and Patient Experience
The Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction.
Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey.
Clinical Implementation and Registry
"At the OSUCCC – James, our mission is to deliver innovative, personalized cancer care to every patient," said David Cohn, M.D., M.B.A., Chief Operating Officer and Chief Medical Officer at The James Cancer Hospital and Solove Research Institute. "We have expanded our strategic partnership from a pilot phase to a full engagement across The James including launching a clinical registry on patients enrolled on the platform. The Veris platform enhances our ability to connect with our patients outside of the hospital and ambulatory clinics."
The partnership represents a significant expansion from the initial pilot phase to full deployment across The James, which is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation.
Future Technology Development
Veris is also developing an implantable physiological monitor, designed to be implanted alongside a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance.
Institutional Background
The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976 and is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI. The center is a global leader in emerging disciplines such as cellular therapy and immuno-oncology, and in 2017 was among the first hospitals in the United States to offer CAR T-cell therapy for blood cancers.